Audit: QRS - Blueberry for Health & Longevity

Audit conducted on 02/09/2026 04:57 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol, time, benefit, risk, monitoring and qualitative content traces to the ER (e.g. one cup/150 g and 22-26 g powder, ER l.351; half-cup null, l.353; split dose, l.363).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names or brands appear in the QRS.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template span names present; marker_#* expanded to 7 rows and qualitative_item# to 5 items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three website=”…” spans and all fixed template markup are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section drawn on by the QRS is empty; no empty-state phrasing is required.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; ER tier emojis and the “Conflicted” warning markers are stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢	45 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty; one contraindication is listed.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty; nine key interactions are listed.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Therapeutic Protocol lists twelve actionable bullets; all three action sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered artery dilation (High benefit), cognition (High), blood pressure & metabolism (Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER Practical Considerations provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	ER benefit headings contain no parentheticals.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	ER risk headings contain no parentheticals.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high carries style=”display: none” (QRS l.603); ER states no risk reaches High.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 7 biomarkers from the ER monitoring table are present.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 5 qualitative markers from the ER are present.

Issues 02/09/2026 04:57

Pass rate 100.00%. No issues found.

Issues 02/09/2026 04:51

1. 1.3 / 2.5 — Split-dose stated as directive: [action_3_value] at line 480 reads “Split morning and evening”, a bare imperative that both recommends an action and strengthens the ER, which merely records at line 363 that one diabetes trial split 22 g into two 11 g doses and that splitting “matches the biphasic dilation response”.

Fixes 02/09/2026 04:51

1. 1.3 / 2.5 — Split-dose stated as directive: [action_3_value] changed from the imperative “Split morning and evening” to the descriptive “Two doses, morning and evening”, and [action_3_sub] reworded from “Trials dosed with meals rather than fasted; splitting matches the two-phase artery response.” to “One trial split the powder across the morning and evening meals; splitting matches the two-phase artery response.” so the cell reports what the ER records instead of recommending an action.

Issues 02/09/2026 04:44

1. 10.2 — Sub-threshold dose absent from Protocol: The Protocol panel spends a slot on “Best time of day” (lines 463–472), an aspect the ER itself closes with “time of day is unconstrained by evidence”, while omitting the ER’s second Therapeutic Protocol bullet “Sub-threshold amounts do not work” — the finding the QRS’s own At-A-Glance leads with (“half a cup does nothing”).
2. 2.7 — Unexplained jargon in protocol sub: action_3_sub (line 484) reads “Matches the biphasic dilation response and eases the fermentable load”; “biphasic” is expanded in the ER but not here, and a plain-language equivalent fits the same budget.

Fixes 02/09/2026 04:44

1. 10.2 — Sub-threshold dose promoted into Protocol: Replaced the action_2 set “Best time of day / With meals” with the ER’s second Therapeutic Protocol bullet: label “Sub-threshold amounts do not work”, value “Half a cup: no effect”, sub “No measurable change on any endpoint over six months; below 75 g daily is untested.”
2. 2.7 — Unexplained jargon in protocol sub: Rewrote action_3_sub from “Matches the biphasic dilation response and eases the fermentable load.” to “Trials dosed with meals rather than fasted; splitting matches the two-phase artery response.”, dropping “biphasic” and retaining the meal-timing fact displaced from action_2.

Issues 02/09/2026 04:34

1. 4.5 — Content exceeds one A4 page: The populated sheet renders well beyond the ~273 mm printable height of the template’s A4 print box; the largest condensable excesses are marker_3_why at line 669 (83 characters against a ~40-character norm for that column), the multi-line marker_7_target and marker_2_target cells, action_1_sub at line 456, and four Key Interactions items that wrap to a second line in the half-width gate column.

Fixes 02/09/2026 04:34

1. 4.5 — Protocol sub-cells condensed: Trimmed action_1_sub from “…freeze-dried powder; the dose used in positive trials.” to “…freeze-dried powder.”, action_2_sub by dropping “which improves tolerance”, and action_3_sub from “Splitting matches … Daily intake is required.” to “Matches the biphasic dilation response and eases the fermentable load.”
2. 4.5 — Time-to-effect sub-cells condensed: Shortened time_1_sub to “Acute widening after a single serving; second rise near six hours.”, time_2_sub to “Concentrated in adults with existing decline.” and time_3_sub to “Ambulatory pressure and metabolic markers moved.”
3. 4.5 — Key Interactions trimmed to one line each: Reduced the three wrapping gate items to “Oral iron salts (ferrous sulfate, gluconate)”, “Antihypertensives (amlodipine, lisinopril)” and “Additive supplements (nitrate, cocoa flavanols)”; all nine ER interactions and their drug lists remain present.
4. 4.5 — Monitoring cells shortened: marker_3_why cut from “Three-month average blood sugar; moved in one diabetes trial, not in pooled analyses” to “Moved in one diabetes trial, not in pooled analyses”, and marker_7_target from “No established consumer target exists…” to “No consumer target exists; track change from own baseline”.
5. 4.5 — Qualitative items compacted: Stripped the trailing explanatory clauses from qualitative_item_1 through qualitative_item_4, leaving the marker itself (e.g. “Perceived exertion at a fixed submaximal effort”).

Issues 02/09/2026 04:27

1. 4.3 — Biomarker label abbreviated: marker_1_name (QRS line 638) reads “Blood pressure (home or 24-hour)”, abbreviating the ER biomarker label “Blood pressure (home or 24-hour average)” (ER line 440).
2. 9.5 — Iron salt name truncated: The first caution item (QRS line 583) renders the ER’s “(ferrous sulfate, ferrous fumarate, ferrous gluconate)” as “(ferrous sulfate, gluconate)”, leaving a bare salt name that is not a drug name used in the ER.

Fixes 02/09/2026 04:27

1. 4.3 — Biomarker label restored to ER wording: marker_1_name changed from “Blood pressure (home or 24-hour)” to “Blood pressure (home or 24-hour average)”, matching the ER biomarker table label verbatim.
2. 9.5 — Iron salt name completed: The first caution item changed from “Oral iron salts (ferrous sulfate, gluconate)” to “Oral iron salts (ferrous sulfate, ferrous gluconate)”, restoring the ER’s drug name.

Issues 02/09/2026 04:16

1. 4.5 — QRS overflows one A4 page: No per-section condensation was applied; against the print box of roughly 703 × 1032 px the stacked content measures about 1.9 pages, driven by the nine full-length caution_items (lines 587–598, ~17 wrapped lines), the 4–5-line action_#_sub cells (lines 456–458, 471–473, 485–486), the seven-row monitoring table with 2–3-line target and why cells (lines 643–743), and the four-line At-A-Glance.

Fixes 02/09/2026 04:16

1. 4.5 — At-A-Glance condensed: Trimmed the summary from 59 words / 358 characters to 46 words / 294 characters while keeping the dose threshold, the responder split, the metabolic disagreement and the iron-timing harm.

2. 4.5 — Protocol sub-cells condensed: Shortened all three action_#_sub cells from 4–5 wrapped lines to 3 (e.g. “Fresh or frozen berries, roughly 300 mg of anthocyanins, or 22–26 g of freeze-dried powder; the dose used in the trials producing positive vascular and cognitive results” → “Fresh or frozen fruit, about 300 mg anthocyanins, or 22–26 g freeze-dried powder; the dose used in positive trials”).

3. 4.5 — Time-to-effect cells condensed: Shortened all three time_#_sub cells to two lines and reduced time_3_label from “Blood pressure & metabolic markers” to “Blood pressure & metabolism” so it no longer wraps.

4. 4.5 — Key Interactions trimmed to fit: Reduced the nine interaction items from roughly 17 wrapped lines to 10 by trimming over-long parenthetical drug lists and dropping the redundant “Over-the-counter” prefixes; every item and at least one named example drug per parenthetical is retained.

5. 4.5 — Monitoring table condensed: Shortened marker_1_name, marker_2_target, marker_5_target and the why cells for markers 1, 2, 4, 5, 6 and 7, cutting the seven-row table from roughly 19 wrapped lines to 11 without dropping any biomarker.

6. 4.5 — Monitoring cadence condensed: Reduced the cadence sentence from 199 to 155 characters while preserving the baseline, 4-week, 12-week, 6–12-month and ferritin-annually schedule including the menstruating-individuals qualifier.

Issues 02/09/2026 04:09

1. 7.2 — At-A-Glance exceeds word limit: The [at_a_glance] span at lines 434–438 contains 65 words, over the 60-word maximum.

Fixes 02/09/2026 04:09

1. 7.2 — At-A-Glance trimmed to word limit: Condensed the [at_a_glance] span from 65 words to 59 (“About a cup” → “A cup”, “already experiencing decline” → “already declining”, “Findings on blood pressure…” → “Blood pressure… findings disagree”, “the uptake of plant-source iron” → “plant-source iron uptake”, “which turns on timing” → “— timing, not amount”), keeping every fact ER-supported.